---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-25-000146"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:17:17.058759+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lifecore Biomedical Q1 revenue up 26% to $31.1M; Adjusted EBITDA turns positive at $3.1M

## Summary
- Revenue $31.1M (+26% YoY), driven by HA manufacturing (+$4.8M) and CDMO growth.
- Net loss narrowed to $10.0M ($0.29 loss per share) from $16.2M ($0.53) a year ago.
- Adjusted EBITDA of $3.1M vs negative $1.8M in prior year; SG&A down $5.9M.
- Affirms transition period guidance: revenue $74-76M, Adjusted EBITDA $12-14M.
- Signed 4 new programs (2 post-quarter); commercial site transfer with large pharma.

## SEC filing metadata
- accession: 0001005286-25-000146
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000146/0001005286-25-000146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000146/lndc-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-25-000146
- JSON: https://secwatch.observer/filing/0001005286-25-000146.json
- Plain text: https://secwatch.observer/filing/0001005286-25-000146.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.